To read this content please select one of the options below:

Pleading scienter after Tellabs in Section 10(b) cases generally and in the “subprime” context

Caryn Jacobs (Partner based at Mayer Brown LLP, Chicago, Ilinois, USA)
Jeffrey M. Strauss (Counsel based at Mayer Brown LLP, Chicago, Ilinois, USA)
John J. Tharp Jr (Partner based at Mayer Brown LLP, Chicago, Ilinois, USA)
Katherine Agonis (Associate based at Mayer Brown LLP, Chicago, Ilinois, USA)

Journal of Investment Compliance

ISSN: 1528-5812

Article publication date: 21 November 2008

393

Abstract

Purpose

The purpose of this paper is to examine the impact the US Supreme Court's Tellabs decision has had on Section 10 (b) cases generally and on cases related to subprime mortgage‐backed securities.

Design/methodology/approach

The paper provides background including provisions of Section 10(b) of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act (PSLRA) of 1995. Analyzes the decision in Tellabs, Inc. v. Makor Issue & Rights, Ltd, recent decisions since Tellabs by the the Second, Seventh, and Ninth Circuits, and decisions in two recent subprime securities cases in which defendants moved to dismiss pursuant to Tellabs; and draws preliminary conclusions from cases that have applied Tellabs so far.

Findings

The PSLRA raised the bar for pleading scienter by requiring a “strong inference”, but the courts of appeals have differed in applying the standard. The Tellabs decision asserted that the PSLRA requires consideration of competing inferences in determination of whether scienter is adequately pleaded. The Supreme Court's “prescription” said the inference of scienter must be more than merely “reasonable” or “permissible”; it must seem to a reasonable person to be at least as cogent and compelling as any opposing inference. One lesson of Tellabs and the Seventh Circuit's decision on remand is that the “plausibility” of scienter allegations requires a fact‐specific inquiry. The Ninth Circuit court found that “deliberate recklessness” is sufficient to allege scienter. In one of the subprime cases, In re 2007 Novastar Financial, Inc., a district court found that a deterioration of a company's business was not evidence of wrongdoing. It is difficult – and premature – to draw firm conclusions from cases that have applied Tellabs so far, but requiring courts to consider competing inferences, requiring the pleadings in question to satisfy more “adjectives”, and requiring the “weighing” of inferences at the pleadings stage would all appear to help defendants. However, Tellabs could help plaintiffs by reversing previous practice in which a “tie” between competing inferences automatically resulted in a victory for the defendant.

Originality/value

The paper offers practical guidance by experienced securities lawyers.

Keywords

Citation

Jacobs, C., Strauss, J.M., Tharp, J.J. and Agonis, K. (2008), "Pleading scienter after Tellabs in Section 10(b) cases generally and in the “subprime” context", Journal of Investment Compliance, Vol. 9 No. 4, pp. 48-67. https://doi.org/10.1108/15285810810922279

Publisher

:

Emerald Group Publishing Limited

Copyright © 2008, Emerald Group Publishing Limited

Related articles